Skip to content
drillr.ai
Sign up

01513.HK

Livzon Pharmaceutical Group, Inc.

HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN

Also listed · 000513.SZ →
HKD 20.40
−1.16%
Ask drillr

  • Sep 9, 2026, 02:41 UTC

    Livzon Pharmaceutical Group announced a special interim dividend of RMB 1.02 per share, totaling over RMB 905 million, approved by its board on September 8, 2026.

    Source:

  • Aug 28, 2026, 02:07 UTC

    Livzon Pharmaceutical Group announced that its controlling subsidiary Livzon Mab received a drug registration certificate from China's National Medical Products Administration for the subcutaneous injection of Lekankitamab (Libaitan), a Class 1 therapeutic biologic approved for treating adult patients with moderate-to-severe plaque psoriasis.

    Source:

  • Aug 23, 2026, 10:03 UTC

    Livzon Pharmaceutical Group announced a connected transaction to acquire a 3.5% stake in Xinbeijiang Pharmaceutical from Zhonghuiyuan for RMB 107 million in cash, increasing its holding from 87.14% to 90.64%.

    Source:

  • Aug 21, 2026, 10:28 UTC

    Livzon Pharmaceutical Group announced its interim results for the six months ended June 2026, with revenue of RMB 4.99967 billion, down 20.28% year-on-year, and net profit of RMB 932 million, down 27.23% year-on-year.

    Source: